The combination of nuclear factor kappa B, cyclo-oxygenase-2 and vascular endothelial growth factor expression predicts poor prognosis in stage II and III colorectal cancer

Anticancer Research

Volumn 34, Issue 11, 2014, Pages 6451-6457

  Kim, Nam Kyu ^a   Park, Jin Kyu ^b   Shin, Eunah ^b   Kim, Young Wan ^c  

^a Yonsei University College of Medicine   (South Korea)

^b Korea CFC Pathology Laboratory   (South Korea)

^c Yonsei University Wonju College of Medicine   (South Korea)

Author keywords

Colorectum; Cyclo oxygenase 2; Neoplasm; Nuclear factor kappa B; Survival; Vascular endothelial growth factor

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; VASCULOTROPIN; PTGS2 PROTEIN, HUMAN; TUMOR MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER CELL; CANCER GRADING; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; COLORECTAL CANCER; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; PROTEIN EXPRESSION; RISK FACTOR; TUMOR VOLUME; COLLOID CARCINOMA; COLORECTAL TUMOR; ENZYME IMMUNOASSAY; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE;

ADENOCARCINOMA, MUCINOUS; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NF-KAPPA B; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84916205007     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Terzic J, Grivennikov S, Karin E and Karin M: Inflammation and colon cancer. Gastroenterology 138(6): 2101-2114.e2105, 2010.
2. Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H and Nagasue N: Cyclo-oxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 6(10): 4064-4068, 2000.
3. Folkman J, Watson K, Ingber D and Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339(6219): 58-61, 1989.
4. Konstantinopoulos PA, Vandoros GP, Karamouzis MV, Gkermpesi M, Sotiropoulou-Bonikou G and Papavassiliou AG: EGF-R is expressed and AP1 and NF-kappaB are activated in stromal myofibroblasts surrounding colon adenocarcinomas paralleling expression of COX2 and VEGF. Cell Oncol 29(6): 477-482, 2007.
5. Charalambous MP, Maihofner C, Bhambra U, Lightfoot T and Gooderham NJ: Up-regulation of cyclooxygenase-2 is accompanied by increased expression of nuclear factor-kappa B and I kappa B kinase-alpha in human colorectal cancer epithelial cells. Br J Cancer 88(10): 1598-1604, 2003.
6. Sakamoto K, Maeda S, Hikiba Y, Nakagawa H, Hayakawa Y, Shibata W, Yanai A, Ogura K and Omata M: Constitutive NFkappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin Cancer Res 15(7): 2248-2258, 2009.
7. Wu AW, Gu J, Li ZF, Ji JF and Xu GW: COX2 expression and tumor angiogenesis in colorectal cancer. World J Gastroenterol 10(16): 2323-2326, 2004.
8. Kim YW, Ko YT, Kim NK, Chung HC, Min BS, Lee KY, Park JP and Kim H: A comparative study of protein expression in primary colorectal cancer and synchronous hepatic metastases: the significance of matrix metalloproteinase-1 expression as a predictor of liver metastasis. Scand J Gastroenterol 45(2): 217-225, 2010.
9. Carrasco JL and Jover L: Estimating the generalized concordance correlation coefficient through variance components. Biometrics 59(4): 849-858, 2003.
10. Witton CJ, Hawe SJ, Cooke TG and Bartlett JM: Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology 45(1): 47-54, 2004.
11. Karin M: NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 1(5): a000141, 2009.
12. Lind DS, Hochwald SN, Malaty J, Rekkas S, Hebig P, Mishra G, Moldawer LL, Copeland EM, 3rd and Mackay S: Nuclear factor-kappa B is up-regulated in colorectal cancer. Surgery 130(2): 363-369, 2001.
13. Yu HG, Yu LL, Yang Y, Luo HS, Yu JP, Meier JJ, Schrader H, Bastian A, Schmidt WE and Schmitz F: Increased expression of RelA/nuclear factor-kappa B protein correlates with colorectal tumorigenesis. Oncology 65(1): 37-45, 2003.
14. Kwon HC, Kim SH, Oh SY, Lee S, Kwon KA, Lee JH, Choi HJ, Park KJ, Lee HS, Roh MS and Kim HJ: Clinicopathological significance of nuclear factor-kappa B, HIF-1 alpha, and vascular endothelial growth factor expression in stage III colorectal cancer. Cancer Sci 101(6): 1557-1561, 2010.
15. Tomozawa S, Tsuno NH, Sunami E, Hatano K, Kitayama J, Osada T, Saito S, Tsuruo T, Shibata Y and Nagawa H: Cyclo-oxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 83(3): 324-328, 2000.
16. Soumaoro LT, Uetake H, Takagi Y, Iida S, Higuchi T, Yasuno M, Enomoto M and Sugihara K: Coexpression of VEGF-C and COX2 in human colorectal cancer and its association with lymph node metastasis. Dis Colon Rectum 49(3): 392-398, 2006.
17. Lim SC, Lee TB, Choi CH, Ryu SY, Min YD and Kim KJ: Prognostic significance of cyclo-oxygenase-2 expression and nuclear p53 accumulation in patients with colorectal cancer. J Surg Oncol 97(1): 51-56, 2008.
18. Choi J and Chang H: The expression of MAGE and SSX, and correlation of COX2, VEGF, and survivin in colorectal cancer. Anticancer Res 32(2): 559-564, 2012.
19. Vandoros GP, Konstantinopoulos PA, Sotiropoulou-Bonikou G, Kominea A, Papachristou GI, Karamouzis MV, Gkermpesi M, Varakis I and Papavassiliou AG: PPAR-γ is expressed and NFκB pathway is activated and correlates positively with COX2 expression in stromal myofibroblasts surrounding colon adenocarcinomas. J Cancer Res Clin Oncol 132(2): 76-84, 2006.
20. Kojima M, Morisaki T, Sasaki N, Nakano K, Mibu R, Tanaka M and Katano M: Increased nuclear factor-κB activation in human colorectal carcinoma and its correlation with tumor progression. Anticancer Res 24( 2b): 675-681, 2004.
21. Peng ZH, Wan DS, Li LR, Chen G, Lu ZH, Wu XJ, Kong LH and Pan ZZ: Expression of COX2, MMP-2 and VEGF in stage II and III colorectal cancer and the clinical significance. Hepatogastroenterology 58(106): 369-376, 2011.
22. Zafirellis K, Agrogiannis G, Zachaki A, Gravani K, Karameris A and Kombouras C: Prognostic significance of VEGF expression evaluated by quantitative immunohistochemical analysis in colorectal cancer. J Surg Res 147(1): 99-107, 2008.
23. Zheng S, Han MY, Xiao ZX, Peng JP and Dong Q: Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma. World J Gastroenterol 9(6): 1227-1230, 2003.
24. Ogino S, Brahmandam M, Kawasaki T, Kirkner GJ, Loda M and Fuchs CS: Combined analysis of COX2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Neoplasia 8(6): 458-464, 2006.
25. Wynter CV, Simms LA, Buttenshaw RL, Biden KG, Young J, Leggett BA, Conrad RJ, Schoch EM, Jass JR and Praga Pillay S: Angiogenic factor VEGF is decreased in human colorectal neoplasms showing DNA microsatellite instability. J Pathol 189(3): 319-325, 1999.